Erika Hamilton focused on breast cancer treatment strategies, particularly for quick relapsers and patients with PI3K mutations. PI3K inhibitors like capivasertib showed a 4.2-month PFS improvement but significant side effects. ADCs like tropic-2 and trastuzumab deruxtecan showed promising results, with PFS improvements of 1.5 months and 4.2 months, respectively.